Acute leukaemia

Scientists have identified a gene – FOXC1 – that, if switched on, causes more aggressive cancer in a fifth of acute myeloid leukaemia (AML) patients

Almost half of teens and young adults with acute myeloid leukaemia (AML) – a typically aggressive form of leukaemia – are cured thanks to improvements in treatment and care, according to research published in the British Journal of Haematology.

US researchers have published details of the genetic makeup of two more forms of cancer – acute myeloid leukaemia (AML) and womb (endometrial) cancer.

A protein – already known to be involved in a cell’s response to stress – called Tetratricopeptide repeat domain 5 (TTC5) is critical to the development of acute myeloid leukaemia (AML), according to a new Cancer Research UK study published in Cell Death and Disease

An estimated 33,000 long-term survivors of childhood cancer – the vast majority of whom are cured – will be living in the UK by the end of 2012.

Acute Myeloid Leukaemia (AML) patients given a new type of ‘smart drug’ in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease, results from a major phase III Cancer Research UK-funded trial led by Cardiff University show today (Saturday).

A drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, majority funded by Cancer Research UK, is published this week in Leukaemia.

Cancer Research UK is today launching a trial to see if male cancer survivors could benefit from hormone replacement therapy (HRT) with testosterone.

Cancer Research UK’s Drug Development Office has opened the first trial of a new type of leukaemia drug.

At least 5,600 more children have survived for at least five years after being diagnosed with cancer than would have done if survival rates had remained as they were in the early 1970s, according to new statistics from Cancer Research UK.